Innovative Estradiol Patch Shows Promise for Prostate Cancer Therapy

A mid-stage study reveals that transdermal estradiol patches may match traditional androgen deprivation therapy in treating prostate cancer with fewer side effects. This approach boosts bone density and minimizes hot flashes compared to LHRH drugs, although breast tissue enlargement remains a concern.

A mid-stage study has uncovered an innovative approach for prostate cancer therapy through the use of transdermal estradiol patches. These patches, which deliver treatment directly through the skin, prove to be as effective as traditional androgen deprivation therapies, offering fewer side effects.

Conducted by Dr. Nick James at The Royal Marsden NHS Foundation Trust, the trial presented at the 2025 ASCO Genitourinary Cancers Symposium showed promising results. The estradiol patch not only suppresses testosterone effectively but also increases bone density and reduces the incidence of hot flashes, common side effects of conventional treatments.

Although enlargement of breast tissue was noted as more common among estradiol patch users, the study indicated that these patches have distinct advantages, including cost-effectiveness. The findings suggest significant benefits for patients troubled by traditional therapies' side effects.

(With inputs from agencies.)